Fulltext

Intranasal Influenza Vaccine in a Working Population

Sendi, Pedram ; Locher, Rebecca ; Bucheli, Bruno ; Battegay, Manuel

In: Clinical Infectious Diseases, 2004, vol. 38, no. 7, p. 974-980

Ajouter à la liste personnelle
    Titre
    • Intranasal Influenza Vaccine in a Working Population
    Auteur
    • Sendi, Pedram. Division of Infectious Diseases and Basel University Hospital, Basel
    • Locher, Rebecca. Division of Infectious Diseases and Basel University Hospital, Basel
    • Bucheli, Bruno. Department of Public Health, Canton Basel-Stadt, Switzerland
    • Battegay, Manuel. Division of Infectious Diseases and Basel University Hospital, Basel
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Clinical Infectious Diseases, 2004, vol. 38, no. 7, p. 974-980. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:295651
    Summary
    In the present study, we assessed the incidence of adverse events and influenza-like symptoms in a working population in Switzerland that was vaccinated against influenza. A total of 12,582 individuals of working age (<65 years old) were offered a free influenza vaccine of their choice (injectable or intranasal vaccine) in October and November 2000. Of these individuals, 1600 were vaccinated against influenza. Ninety-seven percent of the vaccine recipients chose the intranasal vaccine, and 3% chose the injectable influenza vaccine. The incidence of influenza-like symptoms and side effects was 13% and 36%, respectively. Individuals who chose the intranasal vaccine were more likely to report side effects (OR, 3.23; 95% CI, 1.29-8.08). Facial paralysis was observed in 11 patients and was the most severe adverse event associated with the intranasal influenza vaccine. As a result of these adverse events, the intranasal vaccine was removed from the market in the fall of 2001